verastem.com (VSTM) Company Sales Revenue

Resilience to geopolitical risks and patent disputes creates a foundation for growth, as confirmed by the sales volume trajectory of Verastem, Inc. (VSTM), where the current value is 0.10. The business potential relies on the development of targeted agents against resistant tumors. Prospects are further strengthened by the completion of trials for ovarian cancer therapies currently preparing for market entry.

VSTM Verastem Revenue and Sales Volume (07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Verastem (VSTM)

- price and consensus price forecast:

Stock Price Verastem Corp|VSTM - Price Target Chart

- market capitalization details:

Market Value Verastem Oncology|VSTM - Enterprise Value

- balance sheet net asset value indicators:

Book Value of One Share Verastem|VSTM - Book Capitalization|Market-to-Book Ratio verastem.com|VSTM - Cumulative Company Assets

- debt and solvency information:

- earnings and multiples data:

VSTM - Net Profit|Expected Net Income Verastem, Inc.|VSTM - P/E Multiple|Projected Price to Earnings Ratio verastem.com|VSTM - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Verastem Oncology|VSTM - Operating profit EBITDA|Net earnings per share (EPS TTM) Verastem|VSTM - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months verastem.com|VSTM - Net earnings per share growth this year|Expected net earnings per share growth next year Verastem, Inc.

- company sales and revenue statistics:

VSTM - Company Sales|Company Projected Revenue Verastem Corp|VSTM - P/S Multiple|Market Cap to Future Revenue Ratio Verastem Oncology

Summary company analysis:Verastem Corp VSTM

The indicator is based on the aggregation of revenue from the sale of goods and services, directly reflecting the liquidity inflow in the financial statements. This metric measures market demand and the effectiveness of the company's product commercialization. For Verastem, Inc. (VSTM), this is an indicator of success in bringing targeted inhibitors against RAS mutations to market. Analyzing the company's total sales on GURU.Markets allows for the differentiation of business expansion phases. The price action on the chart serves as a signal regarding the scalability of the solid tumor therapy.

Competing companies